

**Biocon Limited**

20th KM Hosur Road  
Electronics City  
Bangalore 560 100, India  
T 91 80 2808 2808  
F 91 80 2852 3423  
CIN : L24234KA1978PLC003417

[www.biocon.com](http://www.biocon.com)

Date of submission: 24<sup>th</sup> May, 2018

To The Secretary Listing Department BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code - 532523	To The Secretary Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 Scrip Code- BIOCON
---	---

Dear Sir/Madam,

**Sub:** Disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011 and Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations 2015.


Pursuant to Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011 and Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations 2015, we wish to inform you that Biocon Limited ("the Promoter") along with the Person Acting in Concert (PAC); Biocon Research Limited, (forming part of the Promoter Group) has decreased the shareholding in Syngene International Limited, subsidiary of the Company by ~2.80 % of total holdings pursuant to sale of shares in the open market on 16<sup>th</sup> and 23<sup>rd</sup> of May 2018, details as under.


SL.NO	SELLER	NO. OF SHARES HELD	NO. OF SHARES SOLD	% OF SALE	DATE OF SALE	REMARKS
1	Biocon Limited	145217843	3765574	1.88	16.05.2018	Biocon Limited intimated to BSE & NSE on 18 <sup>th</sup> May 2018 towards achieving Minimum Public Shareholding by Syngene International Limited.
2	Biocon Limited	141452269	143327	0.07	23.05.2018	
3	Biocon Research Limited	1866673	1688229	0.84	23.05.2018	

Please find enclosed the form in respect of the said disclosure.

We request you to kindly take this to your record as per the requirement of Listing Regulations and oblige.

Thanking You,  
Yours faithfully  
For Biocon Limited

  
Akhilesh Nand  
Chief Compliance Officer  
Encl: As above



**Biocon Limited**

20th KM Hosur Road  
Electronics City  
Bangalore 560 100, India  
T 91 80 2808 2808  
F 91 80 2852 3423  
CIN : L24234KA1978PLC003417

**Disclosures under Regulation 29(2) of SEBI**

**(Substantial Acquisition of Shares and Takeovers)  
Regulations, 2011**

[www.biocon.com](http://www.biocon.com)

1.	Name of the Target Company (TC)	Syngene International Limited		
2.	Name(s) of the Acquirer and Persons Acting in Concert (PAC) with the acquirer	Biocon Limited & Biocon Research Limited		
3.	Whether the acquirer belongs to Promoter/Promoter group	Promoter Group		
4.	Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited and National Stock Exchange of India Limited		
5.	Details of the disposal are as follows	<b>Number</b>	<b>% w.r.t. total share/voting capital wherever applicable(*)</b>	<b>% w.r.t. total diluted share/voting capital of the TC(**)</b>
	<b>Before the sale under consideration, holding of :</b>			
	a) Shares carrying voting rights	(***) 147084516	73.54	73.54
	b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	NIL	NIL	NIL
	c) Voting rights (VR) otherwise than by shares	NIL	NIL	NIL
	d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	NIL	NIL	NIL
	<b>e) Total (a+b+c+d)</b>	147084516	73.54	73.54
	<b>Details of sale</b>			
	a) Shares carrying voting rights acquired/sold	5597130	2.80	2.80
	b) VRs acquired /sold otherwise than by shares	NIL	NIL	NIL
	c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold	NIL	NIL	NIL
	d) Shares encumbered / invoked/released by the acquirer	NIL	NIL	NIL
	<b>e) Total (a+b+c+d)</b>	5597130	2.80	2.80
	<b>After the sale, holding of:</b>			
	a) Shares carrying voting rights	141487386	70.74	70.74
	b) Shares encumbered with the acquirer	NIL	NIL	NIL
	c) VRs otherwise than by shares	NIL	NIL	NIL
	d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	NIL	NIL	NIL
	<b>e) Total (a+b+c+d)</b>	141487386	70.74	70.74
6.	Mode of sale	Open Market		

7.	Date of sale of shares	16.05.2018 & 23.05.2018
8.	Equity share capital / total voting capital of the TC before the said sale	20,00,00,000
9.	Equity share capital / total voting capital of the TC after the said sale	20,00,00,000
10.	Total diluted share/voting capital of the TC after the said sale	20,00,00,000

(\*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Regulation 31 of SEBI Listing Obligations and Disclosure Requirements.

(\*\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(\*\*\*) Both Biocon Limited and Biocon Research Limited before the sale on 16<sup>th</sup> May and 23<sup>rd</sup> May 2018.

Thanking You,  
Yours faithfully  
For Biocon Limited



Akhilesh Nand  
Chief Compliance Officer

CC

To,  
Syngene International Ltd,  
Biocon Park , SEZ,  
Bommasandra Industrial Area - Phase-IV  
Bommasandra-Jigani Link Road,  
Bangalore 560 099  
India